The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 mg. Shares of Zydus Lifesciences Ltd ended at ₹901.15, up by ₹7.85, or 0.88%, on the BSE.
The company got the nod to manufacture and market apalutamide tablets, 60 mg, the generic equivalent of Erleada tablets, 60 mg. Shares of Zydus Lifesciences Ltd ended at ₹901.15, up by ₹7.85, or 0.88%, on the BSE.